SCHEMBL1361594

SCHEMBL1361594

ClC(c1ccccc1)(c1ccccc1)c1ccc(C(c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
CYP1A2 P05177 1/20 0.42
CYP19A1 P11511 2/20 0.42
KCNN4 O15554 5/20 0.39
ALDH1A1 P00352 3/20 0.39
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
CYP3A4 P08684 1/20 0.36
MAPK1 P28482 1/20 0.35
KIF11 P52732 2/20 0.33
TAAR1 Q96RJ0 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chlorotriphenylmethane SCHEMBL461 0.88 TSHR (0.65) TSHRCYP1A2CYP19A1KCNN4ALDH1A1
Chlorotriphenylmethane SCHEMBL16781670 0.88 TSHR (0.65) TSHRCYP1A2CYP19A1KCNN4ALDH1A1
Chlorotriphenylmethane SCHEMBL29446246 0.85 TSHR (0.61) TSHRCYP1A2CYP19A1KCNN4ALDH1A1
Chlorotriphenylmethane SCHEMBL7567317 0.85 TSHR (0.61) TSHRCYP1A2CYP19A1KCNN4ALDH1A1
Chlorotriphenylmethane SCHEMBL113884 0.85 TSHR (0.61) TSHRCYP1A2CYP19A1KCNN4ALDH1A1
Chlorotriphenylmethane SCHEMBL7246540 0.85 TSHR (0.61) TSHRCYP1A2CYP19A1KCNN4ALDH1A1
Chlorotriphenylmethane SCHEMBL11237663 0.85 TSHR (0.61) TSHRCYP1A2CYP19A1KCNN4ALDH1A1
SCHEMBL9846771 0.85 KCNN4 (0.50) TSHRCYP1A2KCNN4ALDH1A1ESR1
SCHEMBL8019320 0.84 TSHR (0.48) TSHRCYP1A2CYP19A1ALDH1A1ESR1
SCHEMBL12305490 0.83 TSHR (0.52) TSHRCYP1A2CYP19A1KCNN4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067571-B2 Antibacterial antisense oligonucleotide and method AVI BIOPHARMA, INC. (US) 2011-11-29 US disclosed
US-7943762-B2 Oligonucleotide analogs having cationic intersubunit linkages AVI BIOPHARMA, INC. (US) 2011-05-17 US disclosed
US-20090088562-A1 Oligonucleotide analogs having cationic intersubunit linkages JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2009-04-02 US disclosed
US-20080194463-A1 Conjugating an arginine-rich carrier to a 3' or 5' end; phosphorodiamidate linkages AVI BIOPHARMA, INC. (US) 2008-08-14 US disclosed
US-4122254-A Process for preparing auranofin SMITHKLINE CORPORATION (US) 1978-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194463-A1 Conjugating an arginine-rich carrier to a 3' or 5' end; phosphorodiamidate linkages RNGTT, BPGM, ARGLU1 TSHR 2883/4885CYP1A2 4869/4885CYP19A1 4616/4885
US-20090088562-A1 Oligonucleotide analogs having cationic intersubunit linkages SLC38A7, SLC43A3, SLC28A3 TSHR 1893/4885CYP1A2 4883/4885CYP19A1 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.